Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK)
1167.HK Stock Price Chart
Explore Jacobio Pharmaceuticals Group Co., Ltd. interactive price chart. Choose custom timeframes to analyze 1167.HK price movements and trends.
1167.HK Company Profile
Discover essential business fundamentals and corporate details for Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
21 Dec 2020
Employees
257.00
Website
https://www.jacobiopharma.comCEO
Yinxiang Wang
Description
Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company's lead drug development programs include two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors comprising JAB-3312 and JAB-3068 for the treatment of esophageal cancer; JAB-8263, a small molecule inhibitor of BET family proteins regulating MYC transcription to treat various cancers; and JAB-21822, an oral small molecule targeting mutant KRAS G12C protein. It is also develops JAB-BX102, a humanized inhibitory antibody against human CD73 for the treatment of PD-1 resistant cancer; JAB-6343, an inhibitor that targets fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma with FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, a tumor metabolic pathway for the treatment of solid tumors; and JAB-BX300, a molecule antibody targeting RAS pathway to treat pancreatic and other solid tumors with KRAS mutations. The company has a strategic collaboration with AbbVie Ireland Unlimited Company to develop and commercialize SHP2 inhibitors. Jacobio Pharmaceuticals Co., Ltd. was incorporated in 2015 and is headquartered in Beijing, China.
1167.HK Financial Timeline
Browse a chronological timeline of Jacobio Pharmaceuticals Group Co., Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 17 Mar 2026
Earnings released on 29 Aug 2025
EPS came in at -$0.09 matching the estimated -$0.09, while revenue for the quarter reached $50.04M , meeting expectations.
Earnings released on 19 Mar 2025
EPS came in at $0.02 falling short of the estimated $0.05 by -65.50%, while revenue for the quarter reached $165.64M , missing expectations by -22.19%.
Earnings released on 30 Aug 2024
EPS came in at -$0.23 surpassing the estimated -$0.29 by +19.42%.
Earnings released on 29 Mar 2024
EPS came in at -$0.28 surpassing the estimated -$0.30 by +7.40%, while revenue for the quarter reached $25.66M , beating expectations by +18.61%.
Earnings released on 30 Aug 2023
EPS came in at -$0.23 surpassing the estimated -$0.31 by +25.46%, while revenue for the quarter reached $43.62M , beating expectations by +34.54%.
Earnings released on 23 Mar 2023
EPS came in at -$0.37 falling short of the estimated -$0.32 by -16.55%, while revenue for the quarter reached $46.76M , missing expectations by -56.11%.
Earnings released on 24 Aug 2022
EPS came in at -$0.20 surpassing the estimated -$0.33 by +39.28%, while revenue for the quarter reached $64.02M .
Earnings released on 31 Dec 2021
EPS came in at -$0.27 surpassing the estimated -$0.32 by +15.60%, while revenue for the quarter reached $116.46M , beating expectations by +264.49%.
Earnings released on 30 Jun 2021
EPS came in at -$0.22 , while revenue for the quarter reached $69.26M .
Earnings released on 31 Dec 2020
EPS came in at -$1.96 falling short of the estimated $13.10 by -114.94%, while revenue for the quarter reached $577.53M , beating expectations by +66.53%.
1167.HK Stock Performance
Access detailed 1167.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.